tetano
Editor, Senior Moderator
Vaccine. 2014 Apr 30. pii: S0264-410X(14)00600-8. doi: 10.1016/j.vaccine.2014.04.062. [Epub ahead of print]
Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: Extending the potential of broadly cross-protecting epitopes.
Wibowo N1, Hughes FK1, Fairmaid EJ2, Lua LH3, Brown LE2, Middelberg AP4.
Author information
Abstract
Influenza A viruses drift and shift, emerging as antigenically distinct strains that lead to epidemics and pandemics of varying severity. Even epitopes associated with broad cross-protection against different strains, such as the ectodomain of matrix protein 2 (M2e), mutate unpredictably. Vaccine protective efficacy is only ensured when the emerging virus lies within the vaccine's cross-protective domain, which is poorly defined in most situations. When virus emerges outside this domain it is essential to rapidly re-engineer the vaccine and hence re-center the cross-protective domain on the new virus. This approach of vaccine re-engineering in response to virus change is the cornerstone of the current influenza control system, based on annual prediction and/or pandemic reaction. This system could become more responsive, and perhaps preventative, if its speed could be improved. Here, we demonstrate vaccine efficacy of a rapidly manufacturable modular capsomere presenting the broadly cross-protecting M2e epitope from influenza. M2e inserted into a viral capsomere at the DNA level was expressed in Escherichia coli as a fusion protein (Wibowo et al., 2013). Immunization of mice with this modular capsomere adjuvanted with conventional aluminum hydroxide induced high (more than 105 endpoint titer) levels of M2e-specific antibodies that reduced disease severity and viral load in the lungs of challenged mice. The combination of rapid manufacturability of modular capsomere presented in this study, and the established cross-protective efficacy of M2e, allow rapid matching of vaccine to the circulating virus and hence rapid re-centering of the vaccine's cross-protective domain onto the virus. This approach synergizes the discussed benefits of broadly cross-protecting epitopes with rapid scale-up vaccine manufacture using microbial cell factories.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Capsomere, E. coli, M2e, Rapid manufacture, Vaccine
PMID:
24795225
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24795225
Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: Extending the potential of broadly cross-protecting epitopes.
Wibowo N1, Hughes FK1, Fairmaid EJ2, Lua LH3, Brown LE2, Middelberg AP4.
Author information
Abstract
Influenza A viruses drift and shift, emerging as antigenically distinct strains that lead to epidemics and pandemics of varying severity. Even epitopes associated with broad cross-protection against different strains, such as the ectodomain of matrix protein 2 (M2e), mutate unpredictably. Vaccine protective efficacy is only ensured when the emerging virus lies within the vaccine's cross-protective domain, which is poorly defined in most situations. When virus emerges outside this domain it is essential to rapidly re-engineer the vaccine and hence re-center the cross-protective domain on the new virus. This approach of vaccine re-engineering in response to virus change is the cornerstone of the current influenza control system, based on annual prediction and/or pandemic reaction. This system could become more responsive, and perhaps preventative, if its speed could be improved. Here, we demonstrate vaccine efficacy of a rapidly manufacturable modular capsomere presenting the broadly cross-protecting M2e epitope from influenza. M2e inserted into a viral capsomere at the DNA level was expressed in Escherichia coli as a fusion protein (Wibowo et al., 2013). Immunization of mice with this modular capsomere adjuvanted with conventional aluminum hydroxide induced high (more than 105 endpoint titer) levels of M2e-specific antibodies that reduced disease severity and viral load in the lungs of challenged mice. The combination of rapid manufacturability of modular capsomere presented in this study, and the established cross-protective efficacy of M2e, allow rapid matching of vaccine to the circulating virus and hence rapid re-centering of the vaccine's cross-protective domain onto the virus. This approach synergizes the discussed benefits of broadly cross-protecting epitopes with rapid scale-up vaccine manufacture using microbial cell factories.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Capsomere, E. coli, M2e, Rapid manufacture, Vaccine
PMID:
24795225
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24795225